Cargando…
Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat type 2 diabetes mellitus. The anti-inflammatory and anti-obesity properties of GLP-1 RAs as well as their moderating effects on multiple pathobiological pathways in asthma pathogenesis may decrease asthma exacerbations, impr...
Autores principales: | Kanwar, Meeta K, Sunku, Ramya, Alruwaili, Faisal, Mufti, Mariam A, Raji, Mukaila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705051/ https://www.ncbi.nlm.nih.gov/pubmed/36457601 http://dx.doi.org/10.7759/cureus.30812 |
Ejemplares similares
-
Effects of glucagon-like peptide 1 receptor agonists on comorbidities
in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019) -
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
por: Sultana, Rizwana, et al.
Publicado: (2022) -
Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
por: Watchorn, David, et al.
Publicado: (2021) -
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
por: Kaplan, Alan G., et al.
Publicado: (2022) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)